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ABSTRACT
Type 1 Diabetes Mellitus (T1DM) is the consequence of autoimmune destruction process of  β cells which associated with Th17 activ-
ity and low 25(OH)D level. This study was aimed to investigate the effect of vitamin D3 supplementation toward 25(OH)D level,
Th17 activity (IL-17) and glycemic control (HbA1c) in pediatric T1DM. This study was designed as randomized clinical trials (RCT),
double-blind, pre and post-test controlled study. Subject was children with T1DM who were divided into two groups: K1: subjects
were treated with insulin 0.5–2 IU/day + vitamin D3 2000 IU/day for 3 months, K2: subjects were treated with insulin 0.5–2 IU/day
+ placebo for 3 months. Levels of 25(OH)D, IL-17 and HbA1c were evaluated after 3 months treatment using ELISA. After 3 months
treatment, results showed that 25(OH)D level was significantly higher in K1 compared with K2 (p = 0.00), IL-17 level was signifi -
cantly lower K1 compared with K2 (p= 0.022). Surprisingly, HbA1c level in K1 was not significantly different with K2 (p = 0.93).
Furthermore, in vitamin D-treated group, 25(OH)D level was elevated significantly after 3 months treatment with vitamin D (p =
0.00), IL-17 level was reduced significantly after 3 months treatment with vitamin D (p= 0.001)  and HbA1c level was reduced in -
significantly after 3 months treatment with vitamin D (p= 0.76). Correlation study showed that there was no correlation between
25(OH)D level with IL-17 level (p= 0.160, r= -0.284) and 25(OH)D with HbA1c (p= 0.62, r= -0.10). This study can be conclude that
vitamin D3 supplementation may elevate the 25(OH)D and reduce IL-17 level but did not change HbA1c level in pediatric T1DM.
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Type 1 Diabetes Mellitus (T1DM) is one of global
health problem whereas its prevalence increase approx-
imately 3% per year. In 2010, as many as 480.000 chil-
dren were suffered from T1DM and its incidence was
75.800 case annually [1, 2, 3]. Management of T1DM
should be comprehensively performed by pediatric en-
docrinologist together with dietician, psychiatrist, psy-
chologist, and educator [4, 5].
In T1DM, destruction of pancreatic  β cells caused
by autoimmune process lead to decreased insulin secre-
tion. The mechanisms underlying pancreatic β cells de-
struction are still unknown, some studies suggest it is
caused by interaction of  multiple  gene  and  environ-
mental exposure [5, 6]. However, there was an involve-
ment of macrophage and T cells in the pathogenesis of
T1DM which lead to inflammation and oxidative stress
[3, 7, 8]. T helper cells 17 (Th17) was involved in the
autoimmunity which lead to destruction of pancreatic
β cells  [4,  9,  10].  Some  chronic  diseases  such  as
T1DM, multiple sclerosis, rheumatoid arthritis, stroke,
cardiovascular disease, and colorectal cancer were asso-
ciated with low level of vitamin D [6, 10]. Vitamin D
has a role as immunomodulatory substances in some
autoimmune disease including T1DM [4, 10].  Interest-
ingly, vitamin D supplementation decrease the risk of
T1DM in dose-dependent manner. Instead of positive
results in some clinical trials, there were some limita-
tions in that cohort designed studies such as sample
size, short follow-up period, and limited control group
[11, 12, 13]. This study was aimed to investigate the ef-
fect of  vitamin D3 supplementation toward 25(OH)D 
level, IL-17 level, and HbA1c in children with T1DM.
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Study design
This  experimental  study  was  designed  as
randomized clinical trial (RCT) double blind, pre and
post-test  control group. Vitamin D3 supplementation
was  administered  for  3  months.  Before  treatment,
subjects with T1DM was measured for 25(OH)D, IL-
17 and HbA1c level. Then, all subjects were randomly
divided  into  2  groups  (K1  and  K2)  as  follow:  K1:
subjects  were  treated  with  insulin  0.5  -  2  IU/day  +
vitamin  D3  2000  IU/day  (D-Vit,  PT.  Gracia
Pharmindo)  for 3  months,  K2:  subjects  were treated
with insulin 0.5 - 2 IU/day + placebo (flour containing
capsules,  PT.  IMFARMIND  Pharmaceuticals
Industries) for 3 months. All procedures in this study
had been approved by Ethical Committee of Research,
dr. Saiful Anwar Public Hospital Malang, Indonesia
Subjects 
As many as 26 subjects were included in this study
(13  subjects  K1  and  13  subjects  K2).  Subjects  were
taken from Pediatric Endocrinology Outpatient Care,
dr.  Saiful  Anwar  General  Hospital,  Malang  during
November  2015-January  2016.  Inclusion  criteria  for
subjects are as follows: diagnosed as T1DM, age 1-18
years  old,  and allowed by his/her  parents  (informed
consent).  Exclusion  criteria  for  subjects  are  T1DM
patients  with  other  autoimmune  disease,  severe
infection, hepatic dysfunction,  renal dysfunction,  and
anemia.
Measurement of vitamin D level
Vitamin  D  level  measurement  was  conducted  at
Clinical  Pathology Laboratory,  Saiful  Anwar  General
Hospital,  Malang.  Blood plasma was stored at -20°C
until  all  sample’s  subject  collected.  Measurement  of
vitamin  D level  was  performed  according  to  manu-
facturer’s  instruction  (Alegria  human vitamin  D kit,
ORG 270).  Biotin  solution 25-D (1  mL) was  added
into  all  tubes,  and  then  mixed  using  vortex  for  10
seconds. As many as 200 µL of dilution callibrator was
added into each well of antibody coated plate and then
incubated  for  2  hours  at  18–25°C.  After  3  times
washing process, 200 µL conjugate was added into each
well.  Microplate  was  covered  with  plastic  and  then
incubated for 30 minutes at 18–25°C. After addition of
200  µL TMB substrate into each well, microplate was
covered  and  then  incubated  for  30  minutes  at  18–
25°C.  Finally,  100  µL  stop  solution  was  added  into
each well. After 30 minutes, specimens were ready for
analysis using ELISA reader at 450 nm.
Measurement of IL-17 level
The method of  malondialdehyde Measurement  of
IL-17  level  was  conducted  at  Physiology  Laboratory,
Faculty  of  Medicine,  Universitas  Brawijaya,  Malang.
Blood plasma was stored at  -20oC until  all  sample’s
subject  collected.  Measurement  of  IL-17  level  was
based on ELISA method according to manufacturer’s
instruction (BioLegend LEGEND MAX™ Human IL-
17A ELISA Kit, catalogue number 433917). First of all,
human  IL-17A  standard  should  be  prepared  in
different concentration (assay buffer A as diluent; 250
pg/mL,  125  pg/mL,  62.5  pg/mL,  31.3  pg/mL,  15.6
pg/mL,  7.8  pg/mL,  and  3.9  pg/mL)  for  making
standard  curve  of  IL-17.  Microplate  washed 4  times
using 300 µL wash buffer.  As many as  50 µL assay
buffer A was added into each well  which containing
standard  dilution  or  sample,  add  50  µL  standard
dilution into each well. After that process, microplate
was sealed using plate sealer and then incubated for 2
hours  while  squeezed  at  200  rpm.  After  mixing
process, microplate was washed using wash buffer for 4
times.  100  µL  human  IL-17A  detection  antibody
solution was added into each well then incubated for 1
hours at room temperature. After incubation process,
microplate was washed using wash buffer for 4 times.
100 µL Avidin-HRP D solution was added into each
well  and  then  incubated  for  30  minutes  at  room
temperature. Microplate was washed again using wash
buffer  for  5  times.  100  µL  substrate  solution F  was
added  into  each  well  and  then  incubated  for  30
minutes in dark room. 100 µL stop solution was added
into each well. After 30 minutes, specimens were ready
for analysis using ELISA reader at 450 nm.
Measurement of HbA1c level
HbA1c  level  measurement  was  conducted  at
Clinical  Pathology Laboratory,  Saiful  Anwar  General
Hospital,  Malang.  As  many  as  1  mL  blood  sample
(whole  blood)  was  collected  into  EDTA-coated  tube
from subjects. 5 µL of sample was mixed with 1.5 ml
wash/ diluent solution before analysis. Measurement of
HbA1c was performed using Bio-Rad D-10TM.
Statistical analysis
Statistical test was based on data distribution and
homogeneity. Statistical differences of 25(OH)D, IL-17,
and  HbA1c  level  between  groups  were  analyzed  by
independent  t-test.  25(OH)D,  IL-17,  and  HbA1c
differences before and after treatment were analyzed by
paired  t-test.  Correlation  of  25(OH)D,  IL-17,  and
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HbA1c level was analyzed by Pearson correlation test. 
Table 1. Subject Characteristics
Characteristics K2 (n=13) K1 (n=13) p-value
Sex 0.691a
- Male 5 6
- Female 8 7
Age (years) 12.15±3.26 12.46±2.99 0.804b
Duration of T1DM 0.695a
- <= 5 y.o 7 6
- > 5 y.o 6 7
Insulin dose 1.19±0.29 1.14±0.16 0.672c
Nutritional status 0.185a
- Good nutrition 11 8
- Undernutrition 2 5
Note: - p-value)a no significant differences using Chi-Square test
- p-value)b no significant differences using t-test
- p-value)c no significant differences using Mann-
Whitney test
Data  was  analyzed  at  95%  confidence  interval  (α=
0.05) using SPSS for Windows version.
Subject characteristics
Subject characteristics such as sex, age, duration of
disease  (T1DM),  insulin  dose,  and  nutritional  status
(age and insulin dose was listed as mean ± standard de-
viation) was shown in Table 1. 
This  study  included  26  subjects  with  age  ranged
from 7-17 years old and its average in each group was
12 years old. This data was in accord with peak incid-
ence of T1DM which ranged from 5 to 7 years old and
at puberty [8, 14, 15]. This study also showed male: fe-
male ratio was 1.4 : 1 and this data similar with previ-
ous  report  about  the  proportion  of  T1DM  patient
based  on  sex  (male  :  female  1  :  1)  [9].  Nutritional
status of subjects was mostly good nutrition. This data
indicated that nutritional status didn’t directly associ-
ated with T1DM because basic mechanism of T1DM
was autoimmune process. 
Level of 25(OH)D, IL-17 and HbA1c
Level of 25(OH)D, IL-17, and HbA1c before treat-
ment with vitamin D3 or placebo was shown in Table
2. As shown in Table 2, there was no significant differ-
ences between K1 and K2 based on 25(OH)D (inde-
pendent t-test, p = 0.36), IL-17 (independent t-test, p =
0.16), and HbA1c level (independent t-test, p = 0.07).
Level  of  25(OH)D, IL-17, and HbA1c after treat-
ment with vitamin D3 or placebo was shown in Table
3. As shown in Table 3, 25(OH)D level was signific-
antly higher in vitamin D-treated group compared with
placeb0-treated  group  (independent  t-test,  p  =  0.00).
Furthermore, IL-17 level was significantly lower in vit-
amin D-treated group as compared to placebo-treated
group  (independent  t-test,  p  =  0.02).  Surprisingly,
HbA1c level in vitamin D-treated group wasn’t signi-
ficantly  different  with  placebo-treated  group  (inde-
pendent t-test, p = 0.93).
Level of 25(OH)D, IL-17, and HbA1c in vitamin D-
treated  group  was  shown  in  Table  4.  As  shown  in
Table 4, 25(OH)D level was elevated significantly after
3 months treatment with vitamin D3 (paired t-test, p =
0.00). IL-17 level was also reduced significantly after 3
months treatment with vitamin D3 (paired t-test, p =
0.01).  However,  HbA1c  was  reduced  insignificantly
after 3 months treatment with vitamin D3 (paired t-
test, p = 0.77). 
Our  data  showed  that  10  subjects  were  suffered
from vitamin D deficiency and 6 subjects were suffered
from  vitamin  D  insufficiency.  Several  observational
studies showed that T1DM subjects  has  low level  of
vitamin D [2, 16, 17]. Children with vitamin D defi-
ciency  has  higher  risk  to  have  autoimmune  disease.
Furthermore,  the  risk  of  T1DM  in  children  with
rachitis at their first year of life was tripled. Supple-
mentation of 2000 IU/day vitamin D had been repor-
ted  to decrease  the  relative  risk of  T1DM (RR 0,22
with CI 0,05-0,89) [11,  13].  This  study showed that
after treatment, 25(OH)D level was significantly higher
in vitamin D-treated  group as  compared to placebo-
treated  group.  Furthermore,  vitamin D supplementa-
tion  2000  IU/day  for  3  months  was  also  increase
25(OH)D significantly at the end of study.
This study showed that IL-17 level in vitamin D-
treated group was significantly lower as compared to
placebo-treated  group  at  the  end  of  study.  Interest-
ingly,  statistical  analysis  in  vitamin D-treated  group,
vitamin D supplementation didn’t significantly reduced
IL-17 level. Our data was similar with previous obser-
vational study which showed that IL-17 secretion and
expression was higher in T1DM subjects [18]. Further-
more, another study also reported that IL-17-secreted
CD4(+) and CD8(+)-T-cells were increased in new on-
set T1DM subjects [19].  Interestingly,  administration
of beta cell autoantigens (proinsulin, insulinoma-asso-
ciated protein, and GAD65 peptide) was increase IL-17
reactivity in 54% subjects with new onset of T1DM as
compared to control (10%) [20]. Currently, IL-17 had
been  investigated  for  its  role  in  pathogenicity  of
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T1DM. Previous study showed that IL-17 increase the 
Table 2. Level of 25(OH)D, IL-17, and HbA1c before treatment
Variable K2 K1 p-valueMean ± SD Mean ± SD
25(OH)D level (ng/mL) 26.78±15.54 21.97±10.27 0.361
IL-17 level (pg/mL) 832.15±272.02 1002.15±325.57 0.161
HbA1c level (%) 11.67±3.21 9.38±2.92 0.070
Note:  - K1: insulin + vitamin D-treated group
- K2 (insulin-only-treated group)
Table 3. Level of 25(OH)D, IL-17, and HbA1c after treatment 
Variable K2 K1 p-value
Mean ± SD Mean ± SD
25(OH)D level (ng/mL) 24.99±12.37 143.52± 29.81 0.000
IL-17 level (pg/mL) 910.34±374.41 582.08± 305.67 0.022
HbA1c level (%) 10.31± 2.36 10.20± 3.89 0.933
Note:  - K1: insulin + vitamin D-treated group
- K2 (insulin-only-treated group)
Table 4. Level  of  25(OH)D,  IL-17,  and  HbA1c  in  treatment
group
Variable Before After p-value
Mean ± SD Mean ± SD
25(OH)D level (ng/mL) 24.37±13.13 84.25 ± 64.45 0.000
IL-17 level (pg/mL) 917.15±306.44 746.21 ± 374.37 0.001
HbA1c level (%) 10.52±3.22 10.25 ± 3.15 0.765
Table 5. Correlation of 25(OH)D level with IL-17 and HbA1c
level
Correlation N Correlationcoefficients (r) p-value
25(OH)D level and IL-17 level 26 -0.284 0.160
25(OH)D level and HbA1c level 26 -0.101 0.624
production of local chemokines which lead to insulitis
and pancreatic beta cells apoptosis [21].
This study indicated that vitamin D supplementa-
tion didn’t change glycemic control of T1DM subjects
based  on  HbA1c  level.  Some  experimental  studies
which investigate the effect of vitamin D supplementa-
tion on glycemic control has controversy results. Biz-
zari and colleagues had been reported that vitamin D3
supplementation at dose 0,25mcg/day didn’t  decrease
HbA1c level as compared to control at several points of
follow-up period (6,  12,  and 24 months)  [22].  Con-
versely, Aljabri and colleagues had been demonstrated
that  HbA1c  level  was  significantly  lower  after  treat-
ment with vitamin D3 4000 IU/day [23]. Later study
only involved vitamin D deficiency subjects (25(OH)D
level < 50 nmol/L) and designed as non blinded and
non randomized controlled trial [23]. This contradict-
ory results  might  be  caused by different  dosage and
duration of vitamin D3 supplementation.
Correlation  level  of  25(OH)D  level  with  IL-17  and
HbA1c
Table 5 showed correlation of 25(OH)D level with
IL-17  and  HbA1c  level.  As  shown  in  Table  5,
25(OH)D level was insignificantly correlated with IL-
17 level (Pearson correlation test, p= 0.160, r= -0.284).
Consistent with previous result, there was no signific-
ant  correlation  between  25(OH)D level  with  HbA1c
level (Pearson correlation test, p= 0.624, r= -0.101).
This study showed that 25(OH) level was insignific-
antly  correlated  with  IL-17  level.  Previous  in  vitro
study showed that administration of 1,25(OH)2D3 to
human T cell CD4(+) CD25(-) decrease its proinflam-
matory cytokines production (IFNγ, IL-17 and IL-21)
and induce adaptive regulatory T cell activator (CTLA-
4 and FoxP3) [24]. This contradictory result might be
caused  by  different  method  in  assessing  IL-17  level.
Ferraro and colleagues reported that there was elevated
regulation  of  Th17  and  functional  defect  of  TReg
CD4+CD25bright cells in PLN tissue and target organ,
but not in peripheral blood [25]. 
Consistently,  25(OH)D  level  was  also  insignific-
antly correlated with HbA1c level. Regarding to the ef-
fect  of  vitamin  D supplementation  on  HbA1c  level,
there were controversial result in the previous studies.
Nwosu and colleagues  reported  that  vitamin  supple-
mentation for 3 months didn’t correlated with HbA1c
level in T1DM patient [26]. Branco and colleagues also
reported  that  there  was  no  correlation  between
25(OH)D level and HbA1c level [27]. Conversely, ob-
servational studies showed that 25(OH)D was negat-
ively correlated with HbA1c level and insulin dosage
requirement in T1DM patient [28, 29].
Active form of vitamin D, 1,25(OH)2D3 possesses
immunomodulator potency that can be used for pre-
vention and treatment  of  autoimmune and infection
disease. Active form of vitamin D could inhibit lymph-
ocyte proliferation and its cytokine production, induce
beta cell tolerance and decrease its sensitivity to apop-
tosis process [7, 14, 30, 31]. Activation of VDR signal-
ing inhibit  DC maturation which represented by de-
crease  DC marker,  class  II  MHC,  costimulator  mo-
lecules (CD40, CD80, and CD86) and other matura-
tion marker (such as CD83) [7, 32]. DC which had
been modulated by 1,25(OH)2D3 will  shift  Th1 and
Th17-dominant  into  Th2-dominant  response  and  in-
crease  IL-10  secretion which  lead  to  proliferation  of
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suppresive Treg [7, 32, 33, 34].
We  concluded  that  vitamin  D3  supplementation
may elevate the 25(OH)D and reduce IL-17 level but
didn’t change HbA1c level in pediatric T1DM.
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